Novel Pentablock Copolymer-Based Nanoparticulate Systems for Sustained Protein Delivery

AAPS PharmSciTech

Volumn 16, Issue 2, 2015, Pages 327-343

  Patel, Sulabh P ^a   Vaishya, Ravi ^a   Pal, Dhananjay ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

block copolymers; controlled drug delivery; IgG; intravitreal; nanoparticles; ocular delivery; pentablock copolymers; posterior segment; protein therapeutics; sustained drug delivery

Indexed keywords

BIOMATERIAL; DELAYED RELEASE FORMULATION; NANOPARTICLE; POLYMER; PROTEIN;

ADMINISTRATION AND DOSAGE; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; MEDICINAL CHEMISTRY; MOLECULAR WEIGHT; MOUSE; PIGMENT EPITHELIUM; PROCEDURES;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELL LINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MOLECULAR WEIGHT; NANOPARTICLES; POLYMERS; PROTEINS; RETINAL PIGMENT EPITHELIUM;

EID: 84929164314     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0196-6     Document Type: Article

References (35)

1. Moutray T, Chakravarthy U. Age-related macular degeneration: current treatment and future options. Ther Adv Chronic Dis. 2011;2(5):325–31.
2. Kulkarni AD, Kuppermann BD. Wet age-related macular degeneration. Adv Drug Deliv Rev. 2005;57(14):1994–2009.
3. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306–9.
4. Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther. 2011;27(4):373–7.
5. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855–9.
6. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29(7):875–912.
7. Jager RD, Aiello LP, Patel SC, Cunningham Jr ET. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676–98.
8. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21(3):178–83.
9. Lee SH, Zhang Z, Feng SS. Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials. 2007;28(11):2041–50.
10. Jia W, Gu Y, Gou M, Dai M, Li X, Kan B, et al. Preparation of biodegradable polycaprolactone/poly (ethylene glycol)/polycaprolactone (PCEC) nanoparticles. Drug Deliv. 2008;15(7):409–16.
11. Bilati U, Allemann E, Doelker E. Poly(D, L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method—processing and formulation issues for enhanced entrapment efficiency. J Microencapsul. 2005;22(2):205–14.
12. Perez C, Castellanos IJ, Costantino HR, Al-Azzam W, Griebenow K. Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers. J Pharm Pharmacol. 2002;54(3):301–13.
13. Putney SD. Encapsulation of proteins for improved delivery. Curr Opin Chem Biol. 1998;2(4):548–52.
14. Kumar TR, Soppimath K, Nachaegari SK. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol. 2006;7(4):261–76.
15. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 2000;17(10):1159–67.
16. Sah H. Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. J Control Release Off J Control Release Soc. 1999;58(2):143–51.
17. Fu K, Pack DW, Klibanov AM, Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res. 2000;17(1):100–6.
18. Zablotna E, Jaskiewicz A, Legowska A, Miecznikowska H, Lesner A, Rolka K. Design of serine proteinase inhibitors by combinatorial chemistry using trypsin inhibitor SFTI-1 as a starting structure. J Pept Sci. 2007;13(11):749–55.
19. Zhang Y, Schwendeman SP. Minimizing acylation of peptides in PLGA microspheres. J Control Release Off J Control Release Soc. 2012;162(1):119–26.
20. Wang J, Chua KM, Wang CH. Stabilization and encapsulation of human immunoglobulin G into biodegradable microspheres. J Colloid Interface Sci. 2004;271(1):92–101.
21. Gou M, Gong C, Zhang J, Wang X, Gu Y, Guo G, et al. Polymeric matrix for drug delivery: honokiol-loaded PCL-PEG-PCL nanoparticles in PEG-PCL-PEG thermosensitive hydrogel. J Biomed Mater Res A. 2010;93(1):219–26.
22. Jwala J, Vadlapatla RK, Vadlapudi AD, Boddu SH, Pal D, Mitra AK. Differential expression of folate receptor-alpha, sodium-dependent multivitamin transporter, and amino acid transporter (B (0, +)) in human retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cell lines. J Ocul Pharmacol Ther. 2012;28(3):237–44.
23. Pissuwan D, Boyer C, Gunasekaran K, Davis TP, Bulmus V. In vitro cytotoxicity of RAFT polymers. Biomacromolecules. 2010;11(2):412–20.
24. Prabhu A, Shelburne CE, Gibbons DF. Cellular proliferation and cytokine responses of murine macrophage cell line J774A.1 to polymethylmethacrylate and cobalt-chrome alloy particles. J Biomed Mater Res. 1998;42(4):655–63.
25. Bilati U, Allemann E, Doelker E. Sonication parameters for the preparation of biodegradable nanocapsules of controlled size by the double emulsion method. Pharm Dev Technol. 2003;8(1):1–9.
26. Tang L, Azzi J, Kwon M, Mounayar M, Tong R, Yin Q, et al. Immunosuppressive activity of size-controlled PEG-PLGA nanoparticles containing encapsulated cyclosporine A. J Transplant. 2012;2012:896141.
27. Bazile D, Prud’homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci. 1995;84(4):493–8.
28. Sabir MI, Xu X, Li L. A review on biodegradable polymeric materials for bone tissue engineering applications. J Mater Sci. 2009;44:5713–24.
29. Huang MH, Li S, Vert M. Synthesis and degradation of PLA–PCL–PLA triblock copolymer prepared by successive polymerization of ε-caprolactone and DL-lactide. Polymer. 2004;45:8675–81.
30. Frank A, Rath SK, Venkatraman SS. Controlled release from bioerodible polymers: effect of drug type and polymer composition. J Control Release Off J Control Release Soc. 2005;102(2):333–44.
31. Huang MH, Li S, Hutmacher DW, Schantz JT, Vacanti CA, Braud C, et al. Degradation and cell culture studies on block copolymers prepared by ring opening polymerization of epsilon-caprolactone in the presence of poly(ethylene glycol). J Biomed Mater Res A. 2004;69(3):417–27.
32. Li S, Molina I, Martinez MB, Vert M. Hydrolytic and enzymatic degradations of physically crosslinked hydrogels prepared from PLA/PEO/PLA triblock copolymers. J Mater Sci Mater Med. 2002;13(1):81–6.
33. Li S, Dobrzynski P, Kasperczyk J, Bero M, Braud C, Vert M. Structure–property relationships of copolymers obtained by ring-opening polymerization of glycolide and epsilon-caprolactone. Part 2. Influence of composition and chain microstructure on the hydrolytic degradation. Biomacromolecules. 2005;6(1):489–97.
34. Chen CC, Chueh JY, Tseng H, Huang HM, Lee SY. Preparation and characterization of biodegradable PLA polymeric blends. Biomaterials. 2003;24(7):1167–73.
35. Park TG. Degradation of poly (D, L-lactic acid) microspheres: effect of molecular weight. J Control Release. 1994;30:161–73.